TAK
Takeda Pharmaceutical Company Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP
$21.06
+1.49%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4734.9B | 4777.5B | 4581.6B | 4263.8B | 4027.5B |
| Cost of Revenue | 1922.5B | 2338.1B | 1580.2B | 1431.5B | 1244.1B |
| Gross Profit | 2812.4B | 2439.3B | 3001.3B | 2832.3B | 2783.4B |
| Operating Expenses | |||||
| R&D Expense | 715.9B | 716.7B | 730.2B | 729.9B | 633.3B |
| SG&A Expense | 1143.5B | 1149.6B | 1104.8B | 1053.8B | 997.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 304.6B | — | 823.8B | 834.4B | 662.3B |
| Total Operating Expenses | 2164.0B | 1866.3B | 2658.7B | 2618.2B | 2292.9B |
| Cost and Expenses | 4086.5B | 4204.4B | 4239.0B | 4049.7B | 3537.0B |
| Operating Income (EBIT) | 648.3B | 573.0B | 342.6B | 214.1B | 490.5B |
| Non-Operating | |||||
| Interest Income | 133.9B | 223.9B | 19.6B | 78.1M | 5.5B |
| Interest Expense | 297.5B | 379.1B | 137.3B | 1.1B | 117.0B |
| Net Interest Income | (163.7B) | (155.2B) | (117.7B) | (984.3M) | (111.2B) |
| Other Non-Op Income/Expense | (246.8B) | (297.2B) | (167.5B) | (161.3B) | (115.4B) |
| Non-Operating Income (excl Interest) | (50.7B) | (82.0B) | (106.5B) | (285.4B) | (129.2B) |
| EBT (Pre-Tax Income) | 401.5B | 275.9B | 175.1B | 52.8B | 375.1B |
| Income Tax Expense | 14.9B | 72.3B | 66.9B | (91.4B) | 58.1B |
| Bottom Line | |||||
| Net Income | 386.4B | 203.3B | 107.9B | 144.1B | 317.0B |
| Earnings from Cont. Ops | 386.6B | 203.6B | 108.1B | 144.2B | 317.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 386.4B | 203.3B | 107.9B | 144.1B | 317.0B |
| Per Share | |||||
| Basic EPS | $122.21 | $63.91 | $34.17 | $46.05 | $102.15 |
| Diluted EPS | $120.23 | $63.91 | $33.62 | $45.58 | $100.97 |
| Revenue Per Share | $1,498.45 | $1,516.59 | $1,426.96 | $1,362.70 | $1,297.67 |
| Shares | |||||
| Basic Shares Outstanding | 3.2B | 3.2B | 3.2B | 3.1B | 3.1B |
| Diluted Shares Outstanding | 3.2B | 3.2B | 3.2B | 3.2B | 3.1B |
| Profitability Metrics | |||||
| EBITDA | 1323.8B | 1376.1B | 1210.5B | 1227.5B | 1284.1B |
| D&A | 624.7B | 721.1B | 761.4B | 728.0B | 664.4B |
| EBIT | 699.1B | 655.0B | 449.1B | 499.5B | 619.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026